论文部分内容阅读
人类胚胎干细胞及诱导多能干细胞研究的一个目标就是将它们成功应用于临床细胞替代疗法,为人类健康做贡献。诱导人类胚胎干细胞及诱导多能干细胞向不同谱系的细胞定向分化是将其应用于临床的前提,系统研究具有不同发育潜能的人多能干细胞间多种差异的分子机制,不仅能够深入理解发育潜能建立的分子基础,而且对筛选和建立符合临床应用标准的人多能干细胞具有重要意义。由同济大学康九红教授领衔的国家重大科学研究计划项目,通过研究不同来源的人类胚胎干细胞及诱导多能干细胞系在多能性、分化潜能、临床有效性和安全性差异的内在本质的区别,对其中所涉及的4个关键科学问题开展了深入研究,取得了若干重要进展。本文就该项目研究的概况、研究进展、实施效果进行回顾与论述,并对后续研究提出展望。
One of the goals of research on human embryonic stem cells and induced pluripotent stem cells is their successful application in clinical cell replacement therapy to contribute to human health. The induction of human embryonic stem cells and the induction of pluripotent stem cells into different lineages of cells is the premise of its clinical application, systematic study of human embryonic stem cells with different development potential of a variety of molecular mechanisms not only to understand the developmental potential Established molecular basis, but also for the screening and establishment of standards in line with clinical application of human pluripotent stem cells is of great significance. The major national scientific research project led by Professor Kang Jiuhong of Tongji University studied the intrinsic essence difference of pluripotency, differentiation potential, clinical efficacy and safety difference between human embryonic stem cells and induced pluripotent stem cells from different origins. The four key scientific issues involved have been studied in depth and some important progress has been made. This article reviews the general situation, research progress and implementation effect of this project, and puts forward the prospect of follow-up research.